E M Hersh, M Del Vecchio, M P Brown, R Kefford, C Loquai, A Testori, S Bhatia, R Gutzmer, R Conry, A Haydon, C Robert, S Ernst, J Homsi, J J Grob, K Kendra, S S Agarwala, M Li, A Clawson, C Brachmann, M Karnoub, I Elias, M F Renschler, A Hauschild
BACKGROUND: The efficacy and safety of nab-paclitaxel versus dacarbazine in patients with metastatic melanoma was evaluated in a phase III randomized, controlled trial. PATIENTS AND METHODS: Chemotherapy-naïve patients with stage IV melanoma received nab-paclitaxel 150 mg/m(2) on days 1, 8, and 15 every 4 weeks or dacarbazine 1000 mg/m(2) every 3 weeks. The primary end point was progression-free survival (PFS) by independent radiologic review; the secondary end point was overall survival (OS)...
November 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology